DK0980252T3 - Terapier til akut nyresvigt - Google Patents

Terapier til akut nyresvigt

Info

Publication number
DK0980252T3
DK0980252T3 DK98919715T DK98919715T DK0980252T3 DK 0980252 T3 DK0980252 T3 DK 0980252T3 DK 98919715 T DK98919715 T DK 98919715T DK 98919715 T DK98919715 T DK 98919715T DK 0980252 T3 DK0980252 T3 DK 0980252T3
Authority
DK
Denmark
Prior art keywords
renal failure
acute renal
therapies
risk
treatment
Prior art date
Application number
DK98919715T
Other languages
English (en)
Inventor
Kuber T Sampath
Charles M Cohen
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK0980252T3 publication Critical patent/DK0980252T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK98919715T 1997-05-05 1998-05-05 Terapier til akut nyresvigt DK0980252T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4561997P 1997-05-05 1997-05-05
PCT/US1998/003197 WO1998050060A1 (en) 1997-05-05 1998-05-05 Therapies for acute renal failure
EP98919715A EP0980252B1 (en) 1997-05-05 1998-05-05 Therapies for acute renal failure

Publications (1)

Publication Number Publication Date
DK0980252T3 true DK0980252T3 (da) 2005-01-31

Family

ID=21938961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98919715T DK0980252T3 (da) 1997-05-05 1998-05-05 Terapier til akut nyresvigt

Country Status (11)

Country Link
US (2) US20100105621A1 (da)
EP (1) EP0980252B1 (da)
JP (2) JP5033276B2 (da)
AT (1) ATE278414T1 (da)
AU (1) AU743510B2 (da)
CA (1) CA2289123A1 (da)
DE (1) DE69826854T2 (da)
DK (1) DK0980252T3 (da)
ES (1) ES2226125T3 (da)
PT (1) PT980252E (da)
WO (1) WO1998050060A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612046B2 (en) 2000-01-31 2009-11-03 Uwe Waldemar Rothenpieler Method for treating kidney disorders
CA2398310C (en) * 2000-01-31 2015-11-24 Uwe Waldemar Rothenpieler Methods for treating kidney disorders with pax2
WO2003000257A1 (en) * 2001-06-26 2003-01-03 Takeda Chemical Industries, Ltd. TGF-ß SUPERFAMILY PRODUCTION/SECRETION PROMOTER
WO2004019876A2 (en) * 2002-08-28 2004-03-11 Curis, Inc. Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
RU2282899C2 (ru) * 2004-01-09 2006-08-27 ГОУ ВПО Омская Государственная Медицинская Академия Способ моделирования инфекции мочевой системы
EP1951751B1 (en) * 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
EP2047862B9 (en) * 2006-07-21 2013-04-10 Chugai Seiyaku Kabushiki Kaisha Remedy for renal disease
US8979797B2 (en) * 2010-12-16 2015-03-17 Ams Research Corporation High pressure delivery system and method for treating pelvic disorder using large molecule therapeutics
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
CN106102761A (zh) 2014-02-07 2016-11-09 宫崎彻 用于肾疾病的预防或治疗剂

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) * 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5266683A (en) * 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5045452A (en) * 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
ATE162223T1 (de) 1989-03-28 1998-01-15 Genetics Inst Osteoinduktive zusammensetzungen
CA2082941A1 (en) 1990-05-16 1991-11-17 Rodney M. Hewick Bone and cartilage inductive proteins
JPH0426624A (ja) 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
ATE146076T1 (de) 1990-06-22 1996-12-15 Du Pont Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
US7056882B2 (en) * 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
CA2363965C (en) * 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
DK0575555T3 (da) 1991-03-11 2001-11-05 Curis Inc Proteininduceret morfogenese
US6194376B1 (en) * 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
EP1637156A1 (en) * 1991-08-30 2006-03-22 Curis, Inc. Systemic administration of osteogenic proteins in the treatment of metabolic bone diseases
ATE197611T1 (de) 1991-08-30 2000-12-15 Creative Biomolecules Inc Screeningverfahren von morphogenischen proteinen
DE69231062T3 (de) * 1991-08-30 2004-07-29 Creative Biomolecules, Inc., Hopkinton Morphogen-induzierte Modulation von entzündlichen Antworten
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
EP0661933B1 (en) 1992-07-31 1998-04-22 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
AU681594B2 (en) * 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
WO1994003600A1 (en) 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Morphogenic protein soluble complex and composition thereof
CA2144514C (en) 1992-09-16 2002-03-26 Thangavel Kuberasampath Morphogen-induced liver regeneration
WO1994010203A2 (en) 1992-11-03 1994-05-11 Creative Biomolecules, Inc. Op-3-induced morphogenesis
CA2157387C (en) 1993-03-04 1998-12-15 David C. Rueger Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
AU690941B2 (en) * 1993-11-15 1998-05-07 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) * 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
ATE493141T1 (de) * 1996-03-22 2011-01-15 Stryker Corp Verfahren zur verbesserten funktionellen erholung der motorischen koordiination, der sprache oder der sinneswahrnehmung nach trauma oder ischämie des zns
US5820589A (en) * 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
DE69826854T2 (de) 2006-02-02
DE69826854D1 (de) 2004-11-11
EP0980252B1 (en) 2004-10-06
US20100105621A1 (en) 2010-04-29
JP2001523264A (ja) 2001-11-20
ES2226125T3 (es) 2005-03-16
JP5033276B2 (ja) 2012-09-26
CA2289123A1 (en) 1998-11-12
AU743510B2 (en) 2002-01-24
US8748378B2 (en) 2014-06-10
WO1998050060A1 (en) 1998-11-12
ATE278414T1 (de) 2004-10-15
JP2009286802A (ja) 2009-12-10
EP0980252A1 (en) 2000-02-23
US20110257093A1 (en) 2011-10-20
PT980252E (pt) 2005-01-31
AU7244398A (en) 1998-11-27

Similar Documents

Publication Publication Date Title
DE69730966D1 (de) Morphogenische behandlung des chronischen nierenversagens
PT980252E (pt) Terapias para insuficiencia renal aguda
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
TR199802421T2 (xx) Doku yenilenmesini d�zenleyen maddeler.
ES2147752T3 (es) Descontaminacion de plaquetas con 8-metoxipsoraleno.
DK0429570T3 (da) Osteoinducerende præparater
EP0846262A4 (en) TISSUE IMAGING AND SPECTROSCOPY, BASED ON THE LIFETIME OF FLUORESCENCE AND OTHER PROGRAMMABLE MEDIA
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
FI956078A0 (fi) Järjestelmä veren virusten inaktivoimiseksi
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
DK308288A (da) Kontraktilt stroempeelement og kompressionsstroempe bestaaende af flere saadanne elementer, til peristaltisk behandling af patienters ekstremiteter
DE69228997D1 (de) Menschliche il-3-varianten
ATE433461T1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
BR9709900A (pt) Proteìnas de ligacão de proteìnas de prìons e usos das mesmas.
ATE499445T1 (de) Menschliche ubiqutin ligase e3. verwendung für die modulation von nf-kappa b
EP1169058A4 (en) INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 Protease
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
TR199900596T2 (xx) Otoim�n hastal�klara kar�� maddeler olarak proteinlerin kullan�m�.
ATE238796T1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten
EP0990441A4 (en) MEDICINES FOR TREATING DIABETIC NEPHROSIS
FI952170L (fi) Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi
NO945031L (no) Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner
DE69821227D1 (de) Verwendung von papovavirus kapsid-proteinen zur verabreichung therapeutischen agentien in nervzellen
FR2764389B1 (fr) Utilisation de venin de crotalus viridis helleri, procede et necessaire pour la determination de la reactivite de la proteine c activee